Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

Fig. 4

Clinical response and remission rates in patients receiving brazikumab during the open-label period. Nonresponder imputation used for missing data. Clinical response was defined as a CDAI total score < 150 or reduction from baseline in CDAI score of ≥ 100 points. Clinical remission was defined as a CDAI total score < 150. CDAI, Crohn’s Disease Activity Index

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us